Why the study?
Does renal impairment affect the pharmacokinetics, safety, and tolerability of oral semaglutide?
Population
71 subjects categorized by renal function: normal, mild impairment, moderate impairment, severe impairment…
Comparison
Once-daily oral semaglutide administered in the… vs Subjects with normal renal function served as…
Follow-up
Up to 21 days after the last dose
Authors
Loading...
May support unchanged dosing in renal impairment; leaves open dedicated outcome trials in advanced CKD.
Does renal impairment affect the pharmacokinetics, safety, and tolerability of oral semaglutide?
Renal impairment and haemodialysis do not significantly affect the pharmacokinetics of oral semaglutide, suggesting no dose adjustment is necessary for these patients.
Granhall et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: